drugset / Trial / NCT05786521
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
Phase 4
Completed
20 enrolled
The University of Texas Health Science Center at San Antonio
National Institute on Aging (NIA) · collab
RandomizedParallel-groupOpen-labelBasic science
Summary
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.
Timeline
- Start
- 2023-04-01
- Primary completion
- 2024-05-20
- Completion
- 2024-05-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Semaglutide | Peptide | 1 mg | — |